Table 3.
A breakdown of all-cause total treatment costs according to risk factors
| Total episodes | Proportion of CAP episodes (%) | Total costs | Proportion of total costs (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Risk factors | n | Outpatient episodes | GW episodes | ICU episodes | $ | % | Outpatient episodes | GW episodes | ICU episodes |
| Total | 34,764 | 41.6% | 57.9% | 0.5% | 136,575,963 | 100.0% | 5.6% | 92.2% | 2.2% |
| Sex | |||||||||
| Male | 21,167 | 41.8% | 57.6% | 0.6% | 83,776,408 | 61.3% | 5.8% | 91.7% | 2.5% |
| Female | 13,597 | 41.2% | 58.5% | 0.4% | 52,799,556 | 38.7% | 5.4% | 93.0% | 1.6% |
| Age group | |||||||||
| 65–74 years | 10,286 | 56.3% | 43.3% | 0.5% | 31,437,785 | 23.0% | 10.8% | 85.5% | 3.7% |
| 75–84 years | 13,577 | 41.3% | 58.1% | 0.6% | 54,022,674 | 39.6% | 5.6% | 92.4% | 2.0% |
| ≥ 85 years | 10,901 | 28.0% | 71.6% | 0.4% | 51,115,505 | 37.4% | 2.5% | 96.1% | 1.3% |
| Comorbidities | |||||||||
| Diabetes mellitus | 3982 | 49.0% | 50.3% | 0.8% | 14,534,072 | 10.6% | 8.9% | 88.2% | 3.0% |
| COPD | 4935 | 49.2% | 50.3% | 0.6% | 16,749,527 | 12.3% | 8.2% | 89.6% | 2.3% |
| Liver function failure | 5793 | 52.1% | 47.4% | 0.5% | 19,154,382 | 14.0% | 9.2% | 88.5% | 2.2% |
| Dementia | 238 | 43.3% | 55.9% | 0.8% | 936,780 | 0.7% | 5.5% | 90.0% | 4.5% |
| Dialysis | 675 | 43.4% | 55.6% | 1.0% | 3,592,463 | 2.6% | 9.1% | 83.9% | 7.0% |
| Rheumatism | 1109 | 55.9% | 43.7% | 0.4% | 3,533,324 | 2.6% | 11.4% | 84.9% | 3.7% |
| Cancer | 3606 | 63.3% | 36.4% | 0.3% | 9,999,506 | 7.3% | 18.6% | 80.0% | 1.4% |
| Prescriptions during previous 6 months | |||||||||
| Oral antibiotics | 3830 | 58.6% | 40.8% | 0.6% | 11,646,586 | 8.5% | 13.7% | 82.8% | 3.5% |
| Inhaled steroids | 2434 | 52.5% | 46.6% | 0.8% | 7,329,868 | 5.4% | 9.7% | 86.9% | 3.4% |
| ACE-I | 1091 | 46.3% | 53.0% | 0.7% | 4,087,905 | 3.0% | 7.0% | 90.8% | 2.2% |
| Statins | 3261 | 51.5% | 47.7% | 0.9% | 10,744,840 | 7.9% | 9.0% | 87.2% | 3.9% |
CAP community-acquired pneumonia, GW general ward, ICU intensive care unit, COPD chronic obstructive pulmonary disease, ACE-I angiotensin-converting enzyme inhibitors